Skip to content

Studying Harms Is Key to Improving Psychedelic-Assisted Therapy—Participants Call for Changes to Research Landscape

Sarah Mcnamee, Neşe Devenot, Meaghan Buisson

JAMA Psychiatry March 29, 2023 DOI: 10.1001/jamapsychiatry.2023.0099 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Viewpoint Peer reviewed
Topics Psychedelic-assisted therapy
Citations 167
Key points Serious adverse events in psychedelic-assisted therapy trials can be linked to therapist-patient interactions.

Abstract

This Viewpoint discusses serious adverse events linked to interactions between therapists and patients in trials of psychedelic-assisted therapy.